Clinical trial
Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic…
NCT00222469 · University of Oklahoma, Other · Completed
Key facts
| NCT number | NCT00222469 |
|---|---|
| Title | Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer |
| Official title | A Phase II Trial of Bevacizumab Plus Gemcitabine™ and Oxaliplatin™ as First Line Therapy in Metastatic or Locally Advanced (Unresectable) Pancreatic Cancer |
| Lead sponsor | University of Oklahoma, Other |
| Collaborators | Genentech, Inc. Industry Sanofi M.D. Anderson Cancer Center |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | bevacizumab, gemcitabine, oxaliplatin |
| Enrollment | 50 |
| Start date | Aug 1, 2005 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Sep 22, 2005 |
| Last update posted | Jul 9, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: